Atossa TherapeuticsATOS
ATOS
About: Atossa Therapeutics Inc is a clinical stage biopharmaceutical company developing proprietary innovative medicines in areas of unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.
Employees: 10
0
Funds holding %
of 6,805 funds
0
Analysts bullish %
of 5 analysts
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
494% more call options, than puts
Call options by funds: $1M | Put options by funds: $169K
113% more first-time investments, than exits
New positions opened: 17 | Existing positions closed: 8
31% more capital invested
Capital invested by funds: $31.7M [Q2] → $41.5M (+$9.77M) [Q3]
12% more funds holding
Funds holding: 77 [Q2] → 86 (+9) [Q3]
0.53% more ownership
Funds ownership: 21.22% [Q2] → 21.74% (+0.53%) [Q3]
24% less repeat investments, than reductions
Existing positions increased: 19 | Existing positions reduced: 25
Research analyst outlook
5 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$6
436%
upside
Avg. target
$6.60
489%
upside
High target
$7
525%
upside
5 analyst ratings
5 positive
100%
0 neutral
0%
0 negative
0%
HC Wainwright & Co. Emily Bodnar 28% 1-year accuracy 41 / 148 met price target | 525%upside $7 | Buy Reiterated | 13 Dec 2024 |
Ascendiant Capital Edward Woo 41% 1-year accuracy 28 / 69 met price target | 525%upside $7 | Buy Maintained | 9 Dec 2024 |
HC Wainwright & Co. Emily Bodnar 28% 1-year accuracy 41 / 148 met price target | 525%upside $7 | Buy Maintained | 13 Nov 2024 |
HC Wainwright & Co. Emily Bodnar 28% 1-year accuracy 41 / 148 met price target | 436%upside $6 | Buy Reiterated | 5 Nov 2024 |
HC Wainwright & Co. Emily Bodnar 28% 1-year accuracy 41 / 148 met price target | 436%upside $6 | Buy Reiterated | 31 Oct 2024 |
Financial journalist opinion
Based on 6 articles about ATOS published over the past 30 days
Neutral
GlobeNewsWire
2 days ago
Atossa Therapeutics to Present Poster Describing the Discovery of Molecules Synergistic with (Z)-endoxifen for the Treatment of Breast Cancer at the 2024 San Antonio Breast Cancer Symposium
Insilico and Chemical Screening Identified Compounds that Synergize with (Z)-endoxifen to Induce Cell Death in MCF-7 Cells, Suggesting Potential Combination Therapies as Breast Cancer Treatments Insilico and Chemical Screening Identified Compounds that Synergize with (Z)-endoxifen to Induce Cell Death in MCF-7 Cells, Suggesting Potential Combination Therapies as Breast Cancer Treatments
Neutral
GlobeNewsWire
3 days ago
Atossa Therapeutics Announces Full Results from Phase 2 KARISMA-Endoxifen Study Demonstrating Statistically Significant Reductions in Mammographic Breast Density
1 MG Dose (Z)-Endoxifen Shows Potential as a Well-Tolerated, Preventative Therapy for Premenopausal Women at Risk of Developing Breast Cancer
Neutral
GlobeNewsWire
4 days ago
Atossa Therapeutics to Present Pharmacokinetic and Tolerability Data from Phase 2 EVANGELINE Trial at the 2024 San Antonio Breast Cancer Symposium
SEATTLE, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”), a clinical stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology with a focus on breast cancer, today announced that three posters involving pharmacokinetic and tolerability data from the Phase 2 EVANGELINE trial will be presented at the 2024 San Antonio Breast Cancer Symposium (SABCS 2024). EVANGELINE is a randomized Phase 2 non-inferiority study investigating (Z)-endoxifen as a neoadjuvant treatment for premenopausal women with estrogen receptor-positive (ER+)/HER2-negative breast cancer.
Neutral
GlobeNewsWire
5 days ago
Atossa Therapeutics Presents Data from Study Investigating Anti-Cancer Activity of (Z)-Endoxifen-Related Compounds at AACR Special Conference in Cancer Research
Novel Compounds Demonstrate Promising Anti-Tumor Activity in Estrogen Receptor-Positive (ERα+) Breast Cancer, Including Endocrine-Resistant Tumors Novel Compounds Demonstrate Promising Anti-Tumor Activity in Estrogen Receptor-Positive (ERα+) Breast Cancer, Including Endocrine-Resistant Tumors
Neutral
GlobeNewsWire
3 weeks ago
Atossa Therapeutics to Present Poster on (Z)-Endoxifen at AACR Special Conference in Cancer Research
Highlights Anti-Cancer Activity of (Z)-Endoxifen-Related Compounds in ERα+ Breast Cancer Highlights Anti-Cancer Activity of (Z)-Endoxifen-Related Compounds in ERα+ Breast Cancer
Neutral
GlobeNewsWire
3 weeks ago
Atossa Therapeutics Announces Five Abstracts Highlighting (Z)-Endoxifen Research Accepted for Presentation at the 2024 San Antonio Breast Cancer Symposium
Detailed results from the KARISMA-Endoxifen trial demonstrating (Z)-endoxifen's ability to significantly reduce mammographic breast density to be featured at conference Detailed results from the KARISMA-Endoxifen trial demonstrating (Z)-endoxifen's ability to significantly reduce mammographic breast density to be featured at conference
Neutral
GlobeNewsWire
1 month ago
Atossa Therapeutics Announces Third Quarter 2024 Financial Results and Provides Corporate Update
SEATTLE, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”) a clinical-stage biopharmaceutical company developing innovative medicines for breast cancer, today announced financial results for the fiscal quarter ended September 30, 2024, and provided an update on recent company developments.
Neutral
GlobeNewsWire
1 month ago
Atossa Therapeutics Appoints Claudia Lopez, DVM, MSc, as Vice President, Clinical Product Development
Dr. Lopez Brings 20+ Years of Global Clinical Development and Leadership to Support Atossa's Mission in Developing Innovative Breast Cancer Therapies Dr. Lopez Brings 20+ Years of Global Clinical Development and Leadership to Support Atossa's Mission in Developing Innovative Breast Cancer Therapies
Neutral
GlobeNewsWire
1 month ago
Atossa Therapeutics Reports Positive KARISMA-Endoxifen Trial Results:
(Z)-Endoxifen Shown to Significantly Reduce Mammographic Breast Density, Potentially Paving the Way for Innovative Cancer Prevention Strategies
Neutral
GlobeNewsWire
1 month ago
Atossa Therapeutics Releases Promising Preliminary Analysis Demonstrating (Z)-Endoxifen's Potential to Rapidly Reduce Ki-67 and Tumor Volume in ER+/HER2- Breast Cancer
(Z)-endoxifen at 10 mg once daily met the primary endpoint with 19/20 (95%) receiving > 75 % of planned treatment in I-SPY-2 Phase 2 Trial
Charts implemented using Lightweight Charts™